Sign up for our Oncology Central weekly news round-up

Will nanobiosensors change therapeutic drug monitoring? The case of methotrexate


Nanobiosensors have emerged as potentially revolutionary technologies to perform therapeutic drug monitoring (TDM). Pharmacokinetics of therapeutic drugs may vary importantly such that TDM can provide valuable information to enable safer treatments and for establishing a personalized course of treatments. In order to transition from academic research to clinical applications, the field of nanobiosensing for TDM must address a series of challenges to achieve the high performance required in TDM and to gain acceptance of both regulatory agencies and the medical community. In this editorial, we discuss the example of methotrexate sensing in serum of patients undergoing cancer treatments using a portable surface plasmon resonance sensor to present the opportunities and challenges facing TDM with nanobiosensors.

Click here to view the full article